Dual inhibition of the terminal oxidases eradicates antibiotic‐tolerant Mycobacterium tuberculosis
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
The approval of bedaquiline has placed energy metabolism in the limelight as an attractive target space for tuberculosis antibiotic development. While bedaquiline inhibits the mycobacterial F 1 F 0 ATP synthase, small molecules targeting other components of the oxidative phosphorylation pathway have been identified. Of particular interest is Telacebec (Q203), a phase 2 drug candidate inhibitor of the cytochrome bcc:aa 3 terminal oxidase. A functional redundancy between the cytochrome bcc:aa 3 and the cytochrome bd oxidase protects M . tuberculosis from Q203‐induced death, highlighting the attractiveness of the bd ‐type terminal oxidase for drug development. Here, we employed a facile whole‐cell screen approach to identify the cytochrome bd inhibitor ND‐011992. Although ND‐011992 is ineffective on its own, it inhibits respiration and ATP homeostasis in combination with Q203. The drug combination was bactericidal against replicating and antibiotic‐tolerant, non‐replicating mycobacteria, and increased efficacy relative to that of a single drug in a mouse model. These findings suggest that a cytochrome bd oxidase inhibitor will add value to a drug combination targeting oxidative phosphorylation for tuberculosis treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191
Betts, J. C., Lukey, P. T., Robb, L. C., McAdam, R. A., & Duncan, K. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.02779.x · Cited by 1,395 · cited 3×
“This uniquely long therapy is believed to be due to a persistent subpopulation of bacteria which is able to survive for extended periods of time without growth, and is tolerant to the first-line drugs (Dick, 2001; Wayne & Sohaskey, 2001; Betts et al, 2002; Boshoff & Barry, 2005).”
BackgroundWayne, L. G., & Hayes, L. G. (1996) · Infection and Immunity · doi:10.1128/iai.64.6.2062-2069.1996 · Cited by 1,141
Nonreplicating Persistence of Mycobacterium Tuberculosis
Wayne, L. G., & Sohaskey, C. D. (2001) · Annual Review of Microbiology · doi:10.1146/annurev.micro.55.1.139 · Cited by 807 · cited 5×
“The latter challenge is attributed to the presence of antibiotic-tolerant subpopulations (Dick, 2001; Wayne & Sohaskey, 2001; Betts et al, 2002; Boshoff & Barry, 2005; Zhang et al, 2012) that can survive in the absence of growth for extended periods of time.”
BackgroundInfluentialGenome plasticity of BCG and impact on vaccine efficacy
Brosch, R., Gordon, S. V., Garnier, T., Eiglmeier, K., Frigui, W., Valenti, P., Dos Santos, S., Duthoy, S., Lacroix, C., Garcia-Pelayo, C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700869104 · Cited by 574 · cited 1×
“…in M. bovis BCG. M. bovis BCG is an excellent surrogate mycobacteria to study the terminal oxidases since its Cyt-bcc:aa3 and Cyt-bd share 100% sequence similarity with the M. tuberculosis H37Rv counterparts (Brosch et al, 2007; Lew et al, 2011; Data ref: Garnier, 2006; Data ref: Lew, 2012).”
BackgroundFord, C. B., Shah, R. R., Maeda, M. K., Gagneux, S., Murray, M. B., Cohen, T., Johnston, J. C., Gardy, J., Lipsitch, M., & Fortune, S. M. (2013) · Nature Genetics · doi:10.1038/ng.2656 · Cited by 457
Tuberculosis — metabolism and respiration in the absence of growth
Boshoff, H. I. M., & Barry, C. E. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1065 · Cited by 448 · cited 4×
“This uniquely long therapy is believed to be due to a persistent subpopulation of bacteria which is able to survive for extended periods of time without growth, and is tolerant to the first-line drugs (Dick, 2001; Wayne & Sohaskey, 2001; Betts et al, 2002; Boshoff & Barry, 2005).”
BackgroundInfluentialDiarylquinolines Are Bactericidal for Dormant Mycobacteria as a Result of Disturbed ATP Homeostasis
Koul, A., Vranckx, L., Dendouga, N., Balemans, W., Van den Wyngaert, I., Vergauwen, K., Göhlmann, H. W. H., Willebrords, R., Poncelet, A., Guillemont, J., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803899200 · Cited by 364
Unique Flexibility in Energy Metabolism Allows Mycobacteria to Combat Starvation and Hypoxia
Berney, M., & Cook, G. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008614 · Cited by 235 · cited 1×
“Even in conditions where oxygen or nutrients are scarce, the energy metabolism pathway remains essential in helping the pathogen adapt and survive (Rao et al, 2008; Berney & Cook, 2010; Gengenbacher et al, 2010).”
BackgroundSelf-citationEnergetics of Respiration and Oxidative Phosphorylation in Mycobacteria
Cook, G. M., Hards, K., Vilchèze, C., Hartman, T., & Berney, M. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.mgm2-0015-2013 · Cited by 212 · cited 2×
“…homeostasis in antibiotic-tolerant hypoxic (Rao et al, 2008) and nutrient-starved (Gengenbacher et al, 2010) M. tuberculosis, opening a scientific rationale to eradicate antibiotic-tolerant, nonreplicating subpopulations (Cook et al, 2014; Hards & Cook, 2018; Kalia et al, 2017; Koul et al, 2008).”
BackgroundMethodSelf-citation
Cited by
Adolph, C., McNeil, M. B., & Cook, G. M. (2022) · mBio · doi:10.1128/mbio.01672-22 · Cited by 32
“We exploited the 231 known synthetically lethality between the two terminal oxidases (the cytochrome bc1:aa3 232 complex and cytochrome bd) (13, 46, 62, 63) as a positive control.”
MethodSelf-citationTargeting Tuberculosis: Novel Scaffolds for Inhibiting Cytochrome bd Oxidase
Seitz, C., Ahn, S.-H., Wei, H., Kyte, M., Cook, G. M., Krause, K. L., & McCammon, J. A. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c00344 · Cited by 11
Self-citationVisualizing the mechanism of quinol oxidation and inhibition of a bd -type oxidase using cryo-EM
van der Velden, T. T., Kayastha, K., Pelser, F., Brünle, S., & Jeuken, L. J. C. (2026) · Science Advances · doi:10.1126/sciadv.aec9946 · Cited by 2
The Mycobacterium smegmatis bd -II terminal oxidase employs a carboxylate shift mechanism
Kovalova, T., Janczak, M., Gamiz-Hernandez, A. P., Lundin, D., Sharma, S., Vilhjálmsdóttir, J., Sjöstrand, D., Kaila, V. R. I., Högbom, M., & Ädelroth, P. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2515348123 · Cited by 1
Metadata
- Authors
- Lee, B. S., Hards, K., Engelhart, C. A., Hasenoehrl, E. J., Kalia, N. P., Mackenzie, J. S., Sviriaeva, E., Chong, S. M. S., Manimekalai, M. S. S., Koh, V. H., Chan, J., Xu, J., Alonso, S., Miller, M. J., Steyn, A. J. C., Grüber, G., Schnappinger, D., Berney, M., Cook, G. M., Moraski, G. C., & Pethe, K.
- Venue
- EMBO Molecular Medicine
- Published
- 2020-12-07
- Volume
- 13
- Issue
- 1
- Pages
- e13207-e13207
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W3112736433
- Cited by
- 97
- References
- 13
- FWCI
- 1.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dual inhibition of the terminal oxidases eradicates antibiotic‐tolerant Mycobacterium tuberculosis. https://app.cochat.ai/papers/10.15252/emmm.202013207
- The paper
- Lee, B. S., Hards, K., Engelhart, C. A., Hasenoehrl, E. J., Kalia, N. P., Mackenzie, J. S., Sviriaeva, E., Chong, S. M. S., Manimekalai, M. S. S., Koh, V. H., Chan, J., Xu, J., Alonso, S., Miller, M. J., Steyn, A. J. C., Grüber, G., Schnappinger, D., Berney, M., Cook, G. M., . . . Pethe, K. (2021). Dual inhibition of the terminal oxidases eradicates antibiotic‐tolerant Mycobacterium tuberculosis. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.202013207
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.